Member Info for dactions

I should have been clearer in my previous message.
My Buy is showing as a Sell and most of today's transactions were BUYS.

Bought a few at close today at .37p so the buy/sell price is clearly arbitary at the moment.

Whether it sails away is very uncertain at the moment on present news level, but I'm hoping that we've seen the last of the lows now that BOOTS is to take it up.

. . . "At £350 per kit that's less than 3000 for 1 Million in revenue.". . . .

Ironman - not sure I follow you ?

At the November 18 Fertility Show there was a promotional offer of £199 which at the time I thought might have been set to match Miracare.com's product offering of $199

Concepta's contents were then exactly the same as today's offering which their website shows as now costing £349 (inc. £57 vat) postage free. Where do the figures of product costing £250 or £300 come from ? Please - anybody.

The Alliance for Regenerative Medicine are running next Thursday a 1 day event in New York titled: The Cell & Gene Therapy Investor day.

https://alliancerm.org/arm-event/arminvestorday/

There are 35 firms presenting, just 15 minute slots, one of which is Reneuron. Olav Hellebo, CEO will be doing the presenting. Could there be some decent shares take-up as a consequence end of next week ?

I can now look at the RENE bulletin boards again.
I think I know how Woodford feels if RENE is anything to go by. Some of my buys were also at his 500p (equivalent) although I was lucky (?) to average my losses down to nearer 300p because of my astute (?) buying at 250p until finally running out of money at 212p. then I closed my eyes !

So, having gone through this so awful ride these past years, there is no way I'm selling my shares, nor trading them. I've now fully discounted them in my mind.

This company is either going to make it very big time or . . . .
Back to closing my eyes - same as Woodford.

The LSE interview with Barney Gray is worth a listen. I have shares in Coro having bought into the Saffron Energy placing - so watching the remorseless share price decline from all the managements machinations with supposedly excellent initial assets has not been a comfortable experience.

Current management have a lot to prove as far as I'm concerned.
I can see why the vitriol is coming from Danial Levi given this seeming manipulative Saffron/Coro management.
However, Coro interview is 6min. 50sec. in and Barney Gray is worth a listen in my opinion.

Watched the whole of Monday's presentation to analysts and as a LTH I can honestly say, I have never seen the merits of Med2002/05 so well presented before. The two principal speakers explained the pros and cons of ED so clearly as well as the excellent opportunties that await any business that can solve the needs.

Just a year to wait to know how well we might do - exciting times.

In my opinion the income figures look good and SoH was at pains I think to point out that most came in the 2nd half. The momentum for this trading year 2019 is excellent. Once the market understands that, the SP should go back to its previous highs.

With two months of trading done, I can see it won't be too long before we get a further trading update which will confirm the rising income trend and thereby move the SP. In the meantime, I'd assume it won't move that far forward ?

Andrew Muir is approx 75 and was in stockbroking. He held 6.354,660 shares in 27/9/17 and today holds 20,974,264 worth approx £1.9m at today's sp price.

That is quite a financial commitment for one man.

Max - I'm not so sure that the Westek acquisition will prove that beneficial - or at least not directly from earnings.

The concept of supposedly 'rugged' it equipment is becoming less unique as time passes because of sold state hard disk now available in massive gigabytes capacity more economically as Chinese/Taiwanese/ you name it ..ese compete against each other bringing the price substantially down. TPG paid £1.5 millions with the promise of paying another £2millions if profit targets are reached over 21 months. Perhaps though if TPG can work their contacts hard they may reap other business.

Their website doesn't add much to their worth either - I know it's only been a few months since purchase, but I would have thought that even in that time, some of the oomph that TPG is showing in it's engineering and maritime sectors could have been applied to Westek.

I've been a LTH in Fox I think since 2012 paying about 25p after I met CG at an Investor show. I've talked with him several times over the years and always he comes over as a pleasant, quietly spoken individual giving trusting comments. At an investment show last year he'd been hard at it talking with scores of investors/would-be ones all day and I bumped into him when he was putting his coat on to go. But he took his coat off and we sat down and talked for 15 mins and I came away that this was to be the year.

But, those preliminary results don't match the conversation we had - they're simply too limited t/o £1.4 million - without being disrespectful - there's a small garden centre down the lane where I live with twice that turnover.

These are very poor results in my opinion for all the capital raising in recent years.
Whilst I have to give credit to CG for getting more capital at 9.5p, when are we going to see serious results that justify this whole business venture ?

Did anyone else notice that Lombard Odier sold approx 2 million shares Monday - advised Tuesday - RNS Wednesday but sold approx 1.5 million shares Tuesday - advised Wednesday - but the RNS (today's) wasn't issued Thursday as it should have been !

To my mind the delay seems deliberate - and could be construed as misleading the market.

"Expect they will continue to reduce in an orderly manner until their holding is around 18%."

I don't know that we can forecast what their holdings may be - their holdings are not quite so straightforward as last month didn't they go up ?

I'm taking the large sale two days ago as more a release of shares into the market to ease stock shortage and hopefully manage the current share price rise so it is can be maintained over the longer term.

Impressive it may be - but I'd be wary at chasing it - I know that's easy to say but I'd like to see some more news rather than chase sentiment.

I think you're right Daringinvestor - good spot.
Below is the extract on FUM's website. I don't know if Growth Company Investor had any more details. Incidentally, why has MED2002 now become known as MED2005 ??

Quote from FUM website:
"CEO James Barder describes Futura as a “medtech” rather than biotech business. Its proprietary technology is
DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this.

A phase III trial in 1,000 patients is underway and will complete by the end of 2019 with a second US study
following. Phase 2 data showed MED2005 worked in patients with mild-to-moderate dysfunction and the new trial uses a higher dose so more severe cases show a response. Futura has enough cash to finish the first trial and take it into 2020. The shares traded as high as 45p in March but were hit badly when attempts to do a deal for a condom-based version fell through. With the company funded through the initial phase III data the shares are an interesting speculation with a market cap of just £12m."

. . .a limited market available in FUM's shares.

Could we see a little recovery after the lows these past months ?

"We’re still wary about the absence of forecasts and, on that basis, wouldn’t buy into OptiBiotix at this stage. But for current shareholders with high risk thresholds, it could be interesting to hang on as OptiBiotix pursues its transition from development to commercialisation."

Thanks AMBIENCE for posting the IC write-up. It's always good to read how others see it . . . but talk about sitting on the fence . . . they must take the biscuit !

The October 2018 RNS mentioned in one of the paragraphs:
"FM57 is a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled, home use, parallel group clinical trial of topically applied GTN and will recruit approximately 1,000 patients with mild, moderate or severe ED and compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2002 against that of placebo. The trial will include at least 60 centres across Central and Eastern Europe to ensure patients are recruited as quickly and efficiently as possible."

The key things about this new trial compared to the earlier one which fired the Shareprice close to 80p was to recruit 1000 men (compared with 242 previously). But it is to be double-blind and placebo-controlled unlike previously I believe. I'm of the impression that the key things they would like to see are (1) does a .2% dose help mild affected patients - which then they perhaps could market off-prescription and (2) how far does a .6% dose help medium to severe patients - these would need to be on prescription.

I'm hoping we'll make rapid progress in recruiting patients for this trial - otherwise, I can't see the shareprice recovering anytime soon.

Can anyone explain tonight's after-hours price extensions please ?